头孢洛扎-他唑巴坦耐药出现的可干预风险因素
50%患者出现TOL-TAZ MIC≥4倍升高,源控制不充分与耐药出现相关,延长3小时输注与较低耐药风险相关,耐药菌常对头孢他啶-阿维巴坦高水平耐药并涉及AmpC突变。
要点
- TOL-TAZ暴露后耐药菌常对CAZ-AVI高水平耐药并伴AmpC突变。
核心结论
- TOL-TAZ治疗期间可能出现耐药,延长输注可能具有保护作用,但样本量小,结果仅为探索性。
主要发现
- TOL-TAZ耐药菌常见突变涉及AmpC和DNA聚合酶。
临床怎么用
- 对碳青霉烯耐药铜绿假单胞菌感染使用TOL-TAZ时,应重视源控制并考虑延长输注以降低耐药风险。
局限性
- 样本量小,结果仅为探索性,需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ceftolozane-tazobactam (TOL-TAZ) affords broad coverage against Pseudomonas aeruginosa. Regrettably, TOL-TAZ resistance has been reported. We sought to identify modifiable risk factors that may reduce the emergence of TOL-TAZ resistance. METHODS: Twenty-eight consecutive patients infected with carbapenem-resistant P. aeruginosa isolates susceptible to TOL-TAZ, treated with ≥72 hours of TOL-TAZ , and with P. aeruginosa isolates available both before and after TOL-TAZ exposure between January 2018 and December 2019 in Baltimore, Maryland, were included. Cases were defined as patients with at least a 4-fold increase in P. aeruginosa TOL-TAZ MICs after exposure to TOL-TAZ. Independent risk factors for the emergence of TOL-TAZ resistance comparing cases and controls were investigated using logistic regression. Whole genome sequencing of paired isolates was used to identify mechanisms of resistance that emerged during TOL-TAZ therapy. RESULTS: Fourteen patients (50%) had P. aeruginosa isolates which developed at least a 4-fold increase in TOL-TAZ MICs(ie, cases). Cases were more likely to have inadequate source control (29% vs 0%, P = .04) and were less likely to receive TOL-TAZ as an extended 3-hour infusion (0% vs 29%; P = .04). Eighty-six percent of index isolates susceptible to ceftazidime-avibactam (CAZ-AVI) had subsequent P. aeruginosa isolates with high-level resistance to CAZ-AVI, after TOL-TAZ exposure and without any CAZ-AVI exposure. Common mutations identified in TOL-TAZ resistant isolates involved AmpC, a known binding site for both ceftolozane and ceftazidime, and DNA polymerase. CONCLUSIONS: Due to our small sample size, our results remain exploratory but forewarn of the potential emergence of TOL-TAZ resistance during therapy and suggest extending TOL-TAZ infusions may be protective. Larger studies are needed to investigate this association.
引用
- Tamma PD, Beisken S, Bergman Y, et al. Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance. Clin Infect Dis. 2021. PMID: 32881997. doi:10.1093/cid/ciaa1306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。